Distinct Signalling Properties of Insulin Receptor Substrate (IRS)-1 and IRS-2 in Mediating Insulin/IGF-1 Action
Overview
Affiliations
Insulin/IGF-1 action is driven by a complex and highly integrated signalling network. Loss-of-function studies indicate that the major insulin/IGF-1 receptor substrate (IRS) proteins, IRS-1 and IRS-2, mediate different biological functions in vitro and in vivo, suggesting specific signalling properties despite their high degree of homology. To identify mechanisms contributing to the differential signalling properties of IRS-1 and IRS-2 in the mediation of insulin/IGF-1 action, we performed comprehensive mass spectrometry (MS)-based phosphoproteomic profiling of brown preadipocytes from wild type, IRS-1 and IRS-2 mice in the basal and IGF-1-stimulated states. We applied stable isotope labeling by amino acids in cell culture (SILAC) for the accurate quantitation of changes in protein phosphorylation. We found ~10% of the 6262 unique phosphorylation sites detected to be regulated by IGF-1. These regulated sites included previously reported substrates of the insulin/IGF-1 signalling pathway, as well as novel substrates including Nuclear Factor I X and Semaphorin-4B. In silico prediction suggests the protein kinase B (PKB), protein kinase C (PKC), and cyclin-dependent kinase (CDK) as the main mediators of these phosphorylation events. Importantly, we found preferential phosphorylation patterns depending on the presence of either IRS-1 or IRS-2, which was associated with specific sets of kinases involved in signal transduction downstream of these substrates such as PDHK1, MAPK3, and PKD1 for IRS-1, and PIN1 and PKC beta for IRS-2. Overall, by generating a comprehensive phosphoproteomic profile from brown preadipocyte cells in response to IGF-1 stimulation, we reveal both common and distinct insulin/IGF-1 signalling events mediated by specific IRS proteins.
Anand S, Patel T Discov Oncol. 2024; 15(1):779.
PMID: 39692821 PMC: 11655924. DOI: 10.1007/s12672-024-01662-1.
Shahidi F, Danielski R Nutrients. 2024; 16(18).
PMID: 39339759 PMC: 11435057. DOI: 10.3390/nu16183159.
Gender Differences in Insulin Resistance: New Knowledge and Perspectives.
Ciarambino T, Crispino P, Guarisco G, Giordano M Curr Issues Mol Biol. 2023; 45(10):7845-7861.
PMID: 37886939 PMC: 10605445. DOI: 10.3390/cimb45100496.
Pathophysiological functions of semaphorins in the sympathetic nervous system.
Mizuno Y, Nakanishi Y, Kumanogoh A Inflamm Regen. 2023; 43(1):30.
PMID: 37291626 PMC: 10249228. DOI: 10.1186/s41232-023-00281-7.
Research progress on the therapeutic effect and mechanism of metformin for lung cancer (Review).
Han P, Zhou J, Xiang J, Liu Q, Sun K Oncol Rep. 2022; 49(1).
PMID: 36367180 PMC: 9685221. DOI: 10.3892/or.2022.8440.